Brief: Orexo Initiates Feasibility Studies Of Amorphox
Jan 9 (Reuters) - Orexo AB ORX.ST :
* OREXO INITIATES EXPLORATORY FEASIBILITY STUDIES OF
AMORPHOX ®
WITH TWO LEADING BIOPHARMACEUTICAL AND VACCINE COMPANIES
* FEASIBILITY STUDIES FOLLOW SUCCESSFUL FORMULATION OF
COVID-19
SPIKE PROTEIN IN AMORPHOX
Source text for Eikon: ID:nWkrbfZ7hp
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens